Sat, Feb 28, 2015, 2:21 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synergy Pharmaceuticals, Inc. Message Board

  • indiansfan407 indiansfan407 Mar 2, 2013 2:15 PM Flag

    beton, question, what is your read on the 15 percent short interest?

    I am long, hold warrants, that is a higher rate than makes me comfortable

    I had NAVB, was at 16% and fell fast and hard

    any words of wisdom thanx in advance

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I posted the following a few weeks ago and some of the figures may have changed a little since my original post but SGYP is a small biotech, having a short hedge against the stock is par for the course. take a look

      short as % of float:
      SGYP: 13%
      IRWD: 23%
      AMRN: 17%
      VVUS: 24%
      OREX: 15%
      ARNA: 30%
      DNDN: 33%

      since many early and mid stage bios fail there will always be a relatively stable short position against these companies. Good news for SGYP is the short position is relatively small compared to its peers (look at irwd) and that has to do with the fact that we are significantly derisked and undervalued given the recent positive data from the Phase III in CIC

      PPS fluctuation on a day to day to week basis is impossible to predict with a small, thinly traded stock like this. IMO the upside given the positive Ph III is very big. it is only a matter of time and we may swing up and down as we wait to see $15-$20 but that is my target and unless I see some negative clinical data or significant delay I'm in for the long haul. Everything else is noise

      GLTAL!

      Sentiment: Strong Buy

 
SGYP
3.02+0.04(+1.34%)Feb 27 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.